A one-day conference exploring the current pharmaceutical pricing landscape. This event brings together leaders from the pharmaceutical industry, policymakers, legal practitioners, and scholars to engage in novel, interdisciplinary discussions to better understand current challenges and articulate best practices to address these issues. Participants assess the current challenges presented in drug pricing policy, from development to delivery, in both the United States and international context. We also explore and articulate best practices to expand access to medicines and develop a plan for disseminating these practices more widely.
See video and slides from this event here
Sponsored by the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School and Global Access in Action at the Berkman Klein Center for Internet and Society at Harvard University, with support from Gilead Sciences, Inc.
Agenda (in development)
8:00 - 8:30am, Registration
8:30 - 8:45am, Welcome Remarks
I. Glenn Cohen, James A. Attwood and Leslie Williams Professor of Law and Faculty Director, Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics, Harvard Law School
Quentin Palfrey, co-Director, Global Access in Action, Berkman Klein Center for Internet and Society at Harvard University
8:45 - 9:30am, Keynote Address
Ronald Piervincenzi, CEO, United States Pharmacopeial Convention
9:30 - 10:45am, Panel I: From Development to Delivery in the United States
Peter B. Bach, Director, Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center
Surya Singh, Vice President and Chief Medical Officer, Specialty Pharmacy, CVS Health
Michael Caljouw, Vice President, State Government and Regulatory Affairs, Blue Cross Blue Shield of Massachusetts
Moderator: Carmel Shachar, Executive Director, Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics and Lecturer at Law, Harvard Law School
10:45 - 11:00am, Break
11:00am - 12:15pm, Panel II: From Development to Delivery Globally
Amy Flood, Senior Vice President, Public Affairs, Gilead Sciences, Inc.
Lauren Galinsky, PIH’s Senior Clinical Operations Advisor, Partners in Health
Hannah Kettler, Senior Program Officer on the Life Sciences Partnerships team at the Bill and Melinda Gates Foundation
Tsveta Milanova, Senior Vice President, Global Value, Access and Policy, Alexion
Moderator: Quentin Palfrey, co-Director, Global Access in Action, Berkman Klein Center for Internet and Society at Harvard University
12:15 - 12:45pm, Keynote Address
Daniel Best, Senior Advisor to the Secretary for Drug Pricing Reform, Food and Drug Administration, U. S. Department of Health and Human Services
12:45 - 1:45pm, Networking Lunch
1:45 - 3:00pm, Panel III: Best Practices in Pricing Policy for Essential Drugs
Peter B. Bach, Director, Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center
- Annette Gaudino, HIV/HCV Project Co-Director, Treatment Action Group (TAG)
Aaron S. Kesselheim, Director, Program on Regulation, Therapeutics, and Law (PORTAL), Brigham & Women’s Hospital, and Associate Professor of Medicine, Harvard Medical School
Jami Taylor, Managing Director, Stanton Park Capital
Moderator: William W. Fisher, WilmerHale Professor of Intellectual Property Law, Harvard Law School, and Faculty Director, Berkman Klein Center for Internet and Society at Harvard University
3:00 - 3:30pm, Keynote Address
- Joe Grogan, Associate Director, Health Programs, Office of Management and Budget
3:30 - 3:45pm, Break
3:45 - 4:30pm, Panel IV: Innovations in Drug Delivery and Policy
Sara Gerke, Research Fellow in Precision Medicine, Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics, Harvard Law School
Muhammad Zaman, Professor, Biomedical Engineering, Boston University
Moderator: Ashveena Gajeelee, Research Fellow, Global Access in Action, Berkman Klein Center for Internet and Society at Harvard University
Register
This event is free and open to the public, but seating is limited and registration is required. Register now!
Sponsored by the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School and Global Access in Action at the Berkman Klein Center for Internet and Society at Harvard University.